U.S. markets open in 4 hours 31 minutes
  • S&P Futures

    3,796.50
    -20.25 (-0.53%)
     
  • Dow Futures

    31,124.00
    -112.00 (-0.36%)
     
  • Nasdaq Futures

    12,595.75
    -86.00 (-0.68%)
     
  • Russell 2000 Futures

    2,189.70
    -16.10 (-0.73%)
     
  • Crude Oil

    60.84
    -0.44 (-0.72%)
     
  • Gold

    1,710.60
    -5.20 (-0.30%)
     
  • Silver

    25.92
    -0.47 (-1.79%)
     
  • EUR/USD

    1.2035
    -0.0032 (-0.26%)
     
  • 10-Yr Bond

    1.4700
    0.0000 (0.00%)
     
  • Vix

    27.46
    +3.36 (+13.94%)
     
  • GBP/USD

    1.3931
    -0.0022 (-0.15%)
     
  • USD/JPY

    107.3410
    +0.3390 (+0.32%)
     
  • BTC-USD

    48,948.74
    -1,894.06 (-3.73%)
     
  • CMC Crypto 200

    982.15
    -5.06 (-0.51%)
     
  • FTSE 100

    6,599.59
    -75.88 (-1.14%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Sage Therapeutics to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Thursday, May 7, 2020, at 4:30 p.m. EDT to announce first quarter 2020 financial results and discuss recent business updates.

The webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200416005088/en/

Contacts

Investor Contact
Jeff Boyle
617-949-4256
Jeff.Boyle@sagerx.com

Media Contact
Maureen L. Suda
617-949-4289
maureen.suda@sagerx.com